Rockville, MD -- (SBWIRE) -- 12/21/2018 -- Clinical care has been evolving with time owing to the increasing scope in the field of science, adoption of advanced technologies, availability of next-generation medical devices and systems, and the increasing emphasis given to development in the healthcare sector. The diagnosis and treatment of diseases with the help of biological markers. Biomarkers are the measurable indications of the biological state that are evaluated with the help of biomarker detection systems are the major developments marked by the medical sector.

The use of biomarker detection systems in the healthcare industry for detecting the severity of diseases followed by the treatment has resulted in increased demand for the biomarker detection systems from the healthcare sector over the past couple of years. The use of biomarker detection systems is not just limited to disease diagnosis but also effective in providing necessary information related to the progression and regression of the disease in the long run.

Get Free Exclusive Sample Copy of This Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=581

Capabilities of the Ultra-Sensitive Biomarker Detection Systems

Known as one of the major players in the biomarker detection systems market and a leading science leading company, Quanterix has been working towards providing effective solutions to the market. With their aim of advancing the science of precision health, the company has showcased their SR-X ultra-sensitive biomarker detection systems. With years of focus on neuro-degeneration, multiple sclerosis, traumatic brain injury, and neuroinflammation, the biomarker detection system developed by Quanterix has the capabilities to detect neurological biomarkers even at ultra-low levels in the blood, far beyond the traditional detection which could only be detected in the cerebrospinal fluid.

Strategic Collaborations to Help Achieve Improved RNA Detection

Furthermore, the company is focused on exploring exceeding possibilities in the biomarker detection systems market with their strategic collaboration with DestiNA Genomics. This collaboration focuses on transforming the detection of microRNA biomarkers. DestiNA Genomics, a manufacturer of patented reagents for the purpose of nucleic acid detection, allows direct quantification of microRNAs to single based resolution, which is being leveraged by Quanterix. The effective combination of the proprietary chemistry of DestiNA and the SR-X ultra-sensitive biomarker detection system offers a potential for PCR-free microRNA biomarker detection to the researchers, which is equipped with ultra-sensitivity and high-specificity. The efforts taken by this collaboration are expected to redefine the process of RNA detection.

Moreover, the ultra-sensitive technology by Quanterix called Simoa Assay Technology provides greater sensitivity to the researchers required for the accurate assessment of biomarkers and measure the neurofilament light chain (NfL) blood levels. With this technology, the company achieves greater advancement in the prevention, early diagnosis, and treatment of various neurological diseases.

Request Brochure of this Report @ https://www.factmr.com/connectus/sample?flag=B&rep_id=581

Biomarker Detection to Transform Healthcare

Biomarker detection has significantly found its way even in the effective cancer diagnosis and detection. The Simoa technology by Quanterix is expected to contribute to the effective diagnostics and treatments of cancer, thereby elevating the healthcare standards. With the development of plasmonic sensors by researchers to effective systems for the biomarker detection, the healthcare industry is focused provides finding new ways to revolutionize clinical care. With market players such as PerkinElmer focusing on the effective biomarker detection and involving in greater research for advancing precision medicine, the biomarker detection segments is expected to flourish significantly.

 The range of biomarker detection systems, kits, and reagents provided by these market players are elevating the capabilities of medical science for better disease detection and treatment. The innovations achieved in biomarker detection have transformed the way diagnostics worked traditionally. Furthermore, the constantly ongoing research showcases the potential that the biomarker detection systems market holds in the forthcoming years.

Ask For Customized Report @ https://www.factmr.com/connectus/sample?flag=RC&rep_id=581

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/